USPTO serial 79212465
PEMPFIX
Reviewed by CopyMark Law Group
Reg. 5440650Status 709
- Filing date
- Status date
- Registration date
- Apr 10, 2018
- Examiner
- TOOLEY, DAVID E
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with PEMPFIX?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
ES
18055 Rostock, DE
18055 Rostock, DE
18055 Rostock, DE
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical and biochemical pharmaceutical preparations for the treatment of or prevention against inflammatory diseases, cancer, infectious diseases, fungal diseases, diseases caused by parasites, eye diseases, diseases of the central and peripheral nervous systems, cardiovascular diseases, diseases affecting the immune system, genetic diseases, single gene disorders, mouth, teeth, skin, hair and ear diseases, bone and blood diseases as well as reproductive system diseases; pharmaceutical and biochemical pharmaceutical preparations for contraception; biochemical and chemical pharamceuticals preparations for use with inflammatory diseases, in particular for use with chronic and autoimmune inflammatory diseases; biochemical and chemical pharmaceuticals preparations for prevention against inflammatory diseases, in particular for prevention against chronic and autoimmune inflammatory diseases; biochemical and chemical pharmaceuticals preparations for prevention against chronic and autoimmune inflammatory skin diseases; biochemical and chemical products for prevention against psoriasis, lupus erythematodes; biochemical and chemical pharmaceuticals preparations for prevention against blister-forming autoimmune dermatoses; biochemical and chemical pharmaceuticals preparations for prevention against pemphigus diseases; biochemical and chemical pharmaceuticals preparations for prevention against pemphigus vulgaris, pemphigus foliaceus, paraneoplastic pemphigus; biochemical and chemical pharmaceuticals preparations for prevention against subepidermal bullous autoimmune dermatoses; biochemical and chemical pharmaceuticals preparations for prevention against bullous pemphigoid, pemphigoid gestationis, linear IgA dermatosis, mucosal pemphigoid, lichen planus pemphigoide, anti-laminin gamal/p200 pemphigoid, epidermolysis bullosa acquisita, dermatitis herpetiformis, in particular against bullous pemphigoid; biochemical and chemical pharmaceuticals preparations for prevention against chronic and autoimmune inflammatory diseases of the central nervous systems, in particular for prevention against multiple sclerosis; biochemical and chemical pharmaceuticals preparations for the treatment of inflammatory diseases, in particular for the treatment of chronic and autoimmune inflammatory diseases; biochemical and chemical pharmaceuticals preparations for the treatment of chronic and autoimmune inflammatory skin diseases, in particular for the treatment of psoriasis, lupus erythematodes; biochemical and chemical pharmaceuticals preparations for the treatment of blister-forming autoimmune dermatoses; biochemical and chemical pharmaceuticals preparations for the treatment of pemphigus diseases; biochemical and chemical pharmaceuticals preparations for the treatment of pemphigus vulgaris, pemphigus foliaceus, paraneoplastic pemphigus; biochemical and chemical pharmaceutical preparations for the treatment of subepidermal bullae autoimmune dermatoses; biochemical and chemical pharmaceuticals preparations for the treatment of bullous pemphigoid, pemphigoid gestationis, linear IgA dermatosis, mucosal pemphigoid, lichen planus pemphigoid, anti-laminin gamal/p200 pemphigoid, epidermolysis bullosa acquisita, dermatitis herpetiformis, in particular against bullous pemphigoid; biochemical and chemical pharmaceuticals preparations for the treatment of chronic and autoimmune inflammatory diseases of the central nervous system, in particular for the treatment of multiple sclerosis; topical and transdermal pharmaceuticals, in particular creams, dispersions, lotions, ointments, fluids, solutions, sprays, plasters, lacquer and filmforming solutions, for the prevention and treatment of skin diseases of the uppermost skin layer or the upper skin layers; surface treatment pharmaceuticals preparations for use as treatments of immune system diseases, inflammatory diseases, skin, hair and ear diseases; oral administration pharmaceuticals preparations, in particular pills, tablets, lozenges, capsules, liquids, solutions, drops, for the prevention and treatment of central nervous system diseases | SECTION 71 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Novalis Investments S.L.
- Other trademarks owned by Immungenetics AG
- Other trademarks owned by Immungenetics AG
- Other trademarks owned by Immungenetics AG
- Other trademarks in Class 005
- Similar marks named PEMPFIX
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Dec 25, 2025 | INNT | TOTAL INVALIDATION PROCESSED BY THE IB | — |
| Dec 4, 2025 | INTS | TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB | — |
| Dec 4, 2025 | INPC | INVALIDATION PROCESSED | — |
| Jun 25, 2025 | INTR | TOTAL INVALIDATION OF REG EXT PROTECTION CREATED | — |
| Oct 25, 2024 | C71T | CANCELLED SECTION 71 | — |
| Apr 10, 2023 | REM3 | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED | — |
| Jul 30, 2021 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Apr 30, 2020 | CHLD | CHANGE OF OWNER RECEIVED FROM IB | — |
| Jul 26, 2019 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Aug 24, 2018 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Jul 30, 2018 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Jul 30, 2018 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Jul 10, 2018 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Apr 10, 2018 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Feb 21, 2018 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Jan 23, 2018 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jan 19, 2018 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Jan 3, 2018 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Jan 3, 2018 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Jan 3, 2018 | NPUB | NOTICE OF PUBLICATION | — |
| Dec 19, 2017 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Nov 27, 2017 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Nov 27, 2017 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Nov 19, 2017 | ALIE | ASSIGNED TO LIE | — |
| Nov 8, 2017 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 18, 2017 | RFNT | REFUSAL PROCESSED BY IB | — |
| Aug 1, 2017 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Aug 1, 2017 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Aug 1, 2017 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Jul 31, 2017 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 25, 2017 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jul 19, 2017 | DOCK | ASSIGNED TO EXAMINER | — |
| Jul 19, 2017 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jul 13, 2017 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |